Reports Q1 revenue $6.7B, consensus $5.92B. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Gilead upgraded to Hold from Reduce at HSBC
- Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
- Gilead price target lowered to $75 from $78 at Cantor Fitzgerald
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024